Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Accrued Expenses

3 Months Ended

Mar. 31, 2023

7. Accrued Expenses

Accrued expenses and other current liabilities consisted of the following (in thousands):

	*March 31,*		*December 31,*
	*2023*		*2022*
Research and development fees	$	5,082	$	5,758
Compensation expense		1,677		3,015
Accrued license obligations		278		245
Accrued accounts payable		1,837		1,245
Lease liabilities		890		859
Other current liabilities		590		483
Collaboration cost-sharing obligation		—		—
Total	$	10,354	$	11,605